Skip to main content
. 2017 Oct 24;61(11):e01325-17. doi: 10.1128/AAC.01325-17

TABLE 3.

Genotypes and susceptibility phenotypes of recombinant CMV strains

Strain Genotype GW275175X
 Letermovir
 Tomeglovir
EC50a SDb No. of replicatesc Fold changed EC50 SD No. of replicates Fold change EC50 SD No. of replicates Fold change
4190 UL56 wild type 1.1 0.28 107 3.8 0.86 100 0.44 0.07 123
4272 UL89 wild type 1.1 0.28 112 3.8 0.88 90 0.47 0.07 142
Selected under GW275175X exposure
    4274 UL89 D344E 10 2.4 113 9.4 7.0 1.1 20 1.8 0.81 0.16 47 1.7
    4283 UL89 C347S 30 8.1 12 27 2.4 0.43 10 0.6 0.16 0.05 9 0.3
    4339 UL89 R351H 9.3 1.2 10 8.5 2.6 0.33 11 0.7 0.17 0.03 10 0.4
    4372 UL56 E769D 0.72 0.17 10 0.7 3.9 1.2 14 1.0 0.33 0.03 8 0.8
    4349 UL56 Q204R 4.6 0.69 8 4.2 5.8 1.3 10 1.5 1.2 0.16 13 2.7
    4357 UL56 Q204R UL89 D344E 22 2.8 8 21 9.4 2.3 9 2.5 2.5 0.22 10 5.8
Selected under letermovir exposure
    4263 UL56 N232Y 0.82 0.22 12 0.8 64 18 12 17 1.2 0.06 8 2.7
    4249 UL56 K258E 0.72 0.15 8 0.7 52 16 12 14 0.14 0.01 8 0.3
    4218 UL56 F261L 0.74 0.25 15 0.7 9.6 1.0 9 2.5 0.44 0.07 13 1.0
    4313 UL56 F261L UL89 D344E 10 1.8 7 10 18 3.3 11 4.8 0.91 0.25 13 2.1
    4271 UL56 M329T 0.90 0.28 12 0.8 17 5.7 12 4.5 0.46 0.11 10 1.1
    4336 UL56 M329T UL89 D344E 11 2.7 8 10 30 6.1 10 8.0 0.98 0.12 10 2.2
    4222 UL56 E237D 0.57 0.12 10 0.5 61 6.0 8 16 0.14 0.02 10 0.3
    4314 UL56 E237D UL89 D344E 8.0 1.8 9 7.4 129 27 8 34 0.27 0.06 9 0.6
    4284 UL89 N320H 4.6 0.97 10 4.2 7.0 0.44 7 1.8 3.0 0.24 11 6.5
    4341 UL89 M359I 0.60 0.11 8 0.5 5.6 1.6 16 1.5 3.4 0.92 14 7.4
Selected under tomeglovir exposure
    4368 UL89 I334V 1.0 0.26 9 0.9 4.0 0.82 10 1.1 0.41 0.10 10 0.9
    4367 UL89 N329S 0.75 0.20 8 0.7 7.7 2.2 13 2.0 6.9 0.63 11 15
    4334 UL89 T350M 5.6 1.2 11 5.1 11 2.5 10 2.8 4.1 0.66 10 8.7
    4323 UL89 V362M 0.69 0.12 7 0.6 4.7 1.1 8 1.2 46 3.7 11 98
    4326 UL89 H389N 0.98 0.32 16 0.9 4.1 0.75 10 1.1 14 2.4 132 29
    4369 UL89 N405D 0.72 0.21 17 0.7 3.9 0.61 12 1.0 6.9 0.54 12 15
    4327 UL89 I334V N405D 0.71 0.18 10 0.6 4.5 0.82 12 1.2 5.6 0.59 9 12
    4337 UL56 L208M 0.71 0.13 11 0.7 3.1 0.29 8 0.8 1.5 0.36 13 3.4
    4330 UL56 E407D 0.99 0.14 8 0.9 5.1 0.63 7 1.3 2.7 0.16 9 6.0
    4358 UL56 H637Q 1.0 0.17 10 0.9 3.4 0.48 7 0.9 0.89 0.09 10 2.0
    4359 UL56 V639M 1.0 0.36 18 0.9 4.0 0.48 8 1.0 4.6 0.42 8 10
    4356 UL56 H637Q V639M 0.91 0.16 8 0.8 4.6 1.0 13 1.2 7.5 1.0 10 17
    4366 UL56 L764M 1.1 0.30 9 1.0 4.3 1.2 12 1.1 0.19 0.02 8 0.4
a

The mean concentration required for 50% SEAP yield reduction (data are in nanomolar for letermovir and micromolar for the other compounds).

b

Standard deviation of EC50 values.

c

Number of replicates of testing (over at least 4 setup dates).

d

Fold change in EC50 compared with that for the wild type (fold changes of >1.5-fold are shown in bold, and underlined data denote cross-resistance). Fold changes of 1.5 are significant at a P value of <0.0025; all fold changes of >1.6 are significant at a P value of <1 × 10−4.